These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 10828672)
1. Low-dose oxybutynin for the treatment of urge incontinence: good efficacy and few side effects. Bemelmans BL; Kiemeney LA; Debruyne FM Eur Urol; 2000 Jun; 37(6):709-13. PubMed ID: 10828672 [TBL] [Abstract][Full Text] [Related]
2. Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial. Zellner M; Madersbacher H; Palmtag H; Stöhrer M; Bödeker RH; Clin Ther; 2009 Nov; 31(11):2519-39. PubMed ID: 20109997 [TBL] [Abstract][Full Text] [Related]
3. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. Versi E; Appell R; Mobley D; Patton W; Saltzstein D Obstet Gynecol; 2000 May; 95(5):718-21. PubMed ID: 10775736 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity. Lehtoranta K; Tainio H; Lukkari-Lax E; Hakonen T; Tammela TL Scand J Urol Nephrol; 2002 Feb; 36(1):18-24. PubMed ID: 12002352 [TBL] [Abstract][Full Text] [Related]
5. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. Davila GW; Daugherty CA; Sanders SW; J Urol; 2001 Jul; 166(1):140-5. PubMed ID: 11435842 [TBL] [Abstract][Full Text] [Related]
6. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. Anderson RU; Mobley D; Blank B; Saltzstein D; Susset J; Brown JS J Urol; 1999 Jun; 161(6):1809-12. PubMed ID: 10332441 [TBL] [Abstract][Full Text] [Related]
7. Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships. Gupta SK; Sathyan G; Lindemulder EA; Ho PL; Sheiner LB; Aarons L Clin Pharmacol Ther; 1999 Jun; 65(6):672-84. PubMed ID: 10391673 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of a new once-daily formulation of oxbutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group. Gleason DM; Susset J; White C; Munoz DR; Sand PK Urology; 1999 Sep; 54(3):420-3. PubMed ID: 10475346 [TBL] [Abstract][Full Text] [Related]
9. [Therapeutic effects of intrarectal administration of oxybutynin]. Radziszewski P; Borkowski A Wiad Lek; 2002; 55(11-12):691-8. PubMed ID: 12715351 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. Dmochowski RR; Davila GW; Zinner NR; Gittelman MC; Saltzstein DR; Lyttle S; Sanders SW; J Urol; 2002 Aug; 168(2):580-6. PubMed ID: 12131314 [TBL] [Abstract][Full Text] [Related]
11. Preliminary evaluation of a new controlled-release oxybutynin in urinary incontinence. Radomski SB; Caley B; Reiz JL; Miceli PC; Harsanyi Z; Darke AC Curr Med Res Opin; 2004; 20(2):249-53. PubMed ID: 15006020 [TBL] [Abstract][Full Text] [Related]
13. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. Madersbacher H; Halaska M; Voigt R; Alloussi S; Höfner K BJU Int; 1999 Oct; 84(6):646-51. PubMed ID: 10510109 [TBL] [Abstract][Full Text] [Related]
14. [Intravesical oxybutynin hydrochloride in the treatment of urge incontinence in the elderly]. Mizunaga M; Miyata M; Kaneko S; Taniguchi N; Yachiku S; Chiba K; Osanai H; Fujisawa M Nihon Hinyokika Gakkai Zasshi; 1996 Jun; 87(6):923-7. PubMed ID: 8753011 [TBL] [Abstract][Full Text] [Related]
15. A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin. Birns J; Lukkari E; Malone-Lee JG BJU Int; 2000 May; 85(7):793-8. PubMed ID: 10792154 [TBL] [Abstract][Full Text] [Related]
16. Transdermal oxybutynin: sticking to the facts. Cartwright R; Cardozo L Eur Urol; 2007 Apr; 51(4):907-14; discussion 914. PubMed ID: 17157979 [TBL] [Abstract][Full Text] [Related]
17. [Intravesical drug therapy in women with severe urge incontinence. Clinical experiences from a department of gynecology]. Johansen JK; Lose G Ugeskr Laeger; 1999 Nov; 161(44):6052-5. PubMed ID: 10778341 [TBL] [Abstract][Full Text] [Related]
18. Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study. Alloussi S; Mürtz G; Braun R; Gerhardt U; Heinrich M; Hellmis E; Horn W; Marschall-Kehrel D; Niklas K; Raabe M; Rössler T; Seibt B; Siemer S; Schultz-Lampel D; Walter H; Wiedeking B; Alloussi S; Bock P; Strugala G; Madersbacher H BJU Int; 2010 Aug; 106(4):550-6. PubMed ID: 20002668 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of oral extended-release oxybutynin in cognitively impaired older nursing home residents with urge urinary incontinence: a randomized placebo-controlled trial. Lackner TE; Wyman JF; McCarthy TC; Monigold M; Davey C J Am Med Dir Assoc; 2011 Nov; 12(9):639-47. PubMed ID: 21450183 [TBL] [Abstract][Full Text] [Related]
20. Transdermal oxybutynin (oxytrol) for urinary incontinence. Dull P Am Fam Physician; 2004 Dec; 70(12):2351-2. PubMed ID: 15617300 [No Abstract] [Full Text] [Related] [Next] [New Search]